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In addition to facilitating the nuclear export of incompletely spliced viral mRNAs, equine infectious anemia
virus (EIAV) Rev regulates alternative splicing of the third exon of the tat/rev mRNA. In the presence of Rev,
this exon of the bicistronic RNA is skipped in a fraction of the spliced mRNAs. In this report, the cis-acting
requirements for exon 3 usage were correlated with sequences necessary for Rev binding and transport of
incompletely spliced RNA. The presence of a purine-rich exon splicing enhancer (ESE) was required for exon
3 recognition, and the addition of Rev inhibited exon 3 splicing. Glutathione-S-transferase (GST)-Rev bound
to probes containing the ESE, and mutation of GAA repeats to GCA within the ESE inhibited both exon 3
recognition in RNA splicing experiments and GST-Rev binding in vitro. These results suggest that Rev regulates alternative splicing by binding at or near the ESE to block SR protein-ESE interactions. A 57-nucleotide
sequence containing the ESE was sufficient to mediate Rev-dependent nuclear export of incompletely spliced
RNAs. Rev export activity was significantly inhibited by mutation of the ESE or by trans-complementation with
SF2/ASF. These results indicate that the ESE functions as a Rev-responsive element and demonstrate that
EIAV Rev mediates exon 3 exclusion through protein-RNA interactions required for efficient export of incompletely spliced viral RNAs.
ing factors to suboptimal splice sites near ESE sequences,
resulting in exon inclusion of alternatively spliced exons.
In addition to the above mechanisms, complex retroviruses
utilize Rev-like pathways to differentially regulate expression
of incompletely spliced RNAs encoding virion structural and
enzymatic proteins and progeny RNA molecules (reviewed in
reference 9). The prototype member of this family, HIV-1 Rev,
binds to the viral pre-mRNA at a specific sequence called the
Rev-responsive element (RRE) (8, 35), multimerizes (24, 34),
and facilitates export of incompletely spliced RNAs from the
nucleus via a CRM1-mediated pathway (13, 14). Equine infectious anemia virus (EIAV) Rev is functionally homologous to
HIV-1 Rev (15) but is less well characterized. EIAV Rev is a
165-amino-acid protein translated from exons 3 and 4 of a
multiply spliced, four-exon, bicistronic mRNA which also encodes the trans-activating protein Tat (Fig. 1) (6). In addition
to promoting nuclear export of incompletely spliced RNA,
EIAV Rev also regulates inclusion of exon 3 of the multiply
spliced RNA. In the presence of Rev, a multiply spliced
mRNA lacking exon 3 is produced (22). Rev variants which are
nuclear export signal (NES) defective have been shown to
mediate alternative splicing (4, 18); however, it is not known if
the alternative splicing function is required for nuclear export
activity. Exon 3 is flanked by a suboptimal splice acceptor and
contains a purine-rich, ESE-like motif which has been shown
to interact with the SR protein SF2/ASF (17). Gontarek and
Derse have proposed that EIAV Rev-mediated skipping of
exon 3 is a consequence of Rev-RNA interactions which directly or indirectly inhibit SF2/ASF (17). We previously
mapped an RRE of Rev to a 534-nucleotide (nt) region containing exon 3 (4), suggesting the possibility that Rev mediates
exon 3 skipping by binding at or near the purine-rich sequence
to disrupt SR protein interactions necessary for exon 3 recognition.

Retroviruses utilize a variety of mechanisms to differentially
express numerous proteins from relatively small genomes
which possess a single transcriptional start site. These mechanisms include, but are not limited to, the use of polyprotein
precursors, ribosomal frameshifting (19), alternative start
codons (6), bicistronic mRNAs (6), and alternative splicing
(29). Alternative splicing allows the production of multiple
viral mRNAs from a single RNA precursor. The simplest retroviruses, such as murine leukemia virus, express only two
mRNAs, an unspliced RNA which serves both as mRNA for
the Gag and Pol proteins and as progeny viral RNA, and a
singly spliced mRNA which encodes the env gene. In contrast,
complex retroviruses, such as human immunodeficiency virus
type 1 (HIV-1), produce at least 20 different mRNAs, including several multiply spliced RNAs that encode small regulatory
proteins (29).
In all retroviruses, alternative splicing requires the presence
of suboptimal splice sites, allowing expression of several
mRNAs from a single pre-RNA. Regulation of suboptimal
splice sites is a complex process mediated in part by cis-acting
RNA sequences that can either enhance or repress recognition
of a splice site by the splicing machinery. Exon-splicing enhancers (ESEs) and silencers (ESSs) have been described for
many virus and cellular RNAs (2, 23). ESEs typically are purine-rich sequences embedded within alternatively spliced exons. The purine-rich sequences mediate exon recognition
through interactions with members of the SR protein family of
splicing factors. SR proteins are both essential splicing factors
and regulators of alternative splicing (reviewed in reference
16). Binding of SR proteins to an ESE recruits essential splic* Corresponding author. Mailing address: Dept. of VMPM, Rm.
1136 Vet Med, Iowa State University, Ames, IA 50011. Phone: (515)
294-5158. Fax: (515) 294-8500. E-mail: scarp@iastate.edu.
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FIG. 1. Organization and splicing patterns of EIAV. Schematic of EIAV genome with open reading frames (ORFs). The tat ORFs are indicated with a t, and the
first exon of rev is marked with an r (location in genome indicated by the shaded region). Splicing patterns and genes expressed are indicated. The ttm ORF encodes
a truncated transmembrane protein of unknown function (3). LTR, long terminal repeat.

Here, we further delineate the role of Rev in exon 3 alternative splicing. Our results indicate that the purine-rich sequence in exon 3 is required for the utilization of the exon 3
splice acceptor, confirming the presence of an ESE within exon
3. RNA gel mobility shift assays and nuclear export assays
demonstrate that Rev binds to the ESE and that this binding
facilitates RNA export. Together, these results indicate that
the exon 3 ESE is an RRE of EIAV. Therefore, Rev mediates
exon 3 alternative splicing by binding the viral pre-mRNA at
the ESE/RRE and interfering with SR protein-ESE interactions.
MATERIALS AND METHODS
PCR and plasmid construction. All plasmid constructs were confirmed by
sequence analysis (Iowa State University DNA Synthesis and Sequencing Facility). DNA templates for splicing substrates were amplified from p33k, a subclone
of the p26 EIAV proviral clone described previously (5). Unless otherwise
indicated, PCRs were performed as directed by the manufacturer (Perkin Elmer,
Foster City, Calif.) using 1 M primers. Standard PCRs consisted of 25 cycles of
1 min of denaturation at 94°C, 1 min of annealing at 50°C, and 1 min of extension
at 72°C, followed by an additional cycle with a prolonged, 5-min extension. All
DNA templates for splicing substrates used a common 5⬘ primer, CTGAAGG
CAATCCAACAAGG, and individual 3⬘ primers to generate the substrates
shown in Fig. 2A. The 3⬘ primers used and the region of EIAV amplified were:
CTCTCTATGATAAGCTTC, EIAV nt 5233 to 5793; CCAGTAGTTCCTGCT
AAGCA, nt 5233 to 5573; TTTCCACCAGTCATTTCTTC, nt 5233 to 5535; and
CAGGTTCATTTCTTGGTCT, nt 5233 to 5490. All nucleotide numbering is
based on that of Kawakami et al. (20). After PCR, fragments were TA cloned
into the pGEM-T Easy vector as directed by the manufacturer (Promega, Madison, Wis.).
The expression plasmid pRevWT was described previously as pcH21 (4).
pDM138, pERRE-All (EIAV nt 5280 to 7534), and pERRE-1 (nt 5280 to 5834)
have also been described previously (4). To construct pERRE-1A, primers containing a ClaI restriction site were used to amplify EIAV nt 5281 to 5795. The
ERRE-1A 5⬘ primer was GGATCGATTTGATATATGGGATTATT, and the
3⬘ primer was GGATCGATCTCTCTATGATAAGCTTC (ClaI sites are underlined). The minRRE sequence (EIAV nt 5485 to 5540) was synthesized as
complementary oligonucleotides with ClaI extensions on the 5⬘ and 3⬘ ends. The
oligonucleotides were heated at 95°C for 5 min and annealed by slow cooling.

The fragment was phosphorylated and then ligated with pDM138. The pGSTRev expression vector contains a cDNA cloned in frame into the BamHI site of
the glutathione-S-transferase (GST) fusion vector pGEX-3X (Amersham Pharmacia Biotech, Piscataway, N.J.).
ESE mutants were constructed by PCR-Ligation-PCR mutagenesis according
to the methods described by Ali et al. (1) using internal primers designed with the
specified mutations shown in Fig. 4A. The two regions were amplified with Vent
DNA polymerase (New England Biolabs, Beverly, Mass.). The 3⬘ fragment was
phosphorylated and ligated with the 5⬘ fragment, and 2 l of the ligation reaction
mixture was PCR amplified with the outer primers described above to amplify
EIAV nt 5233 to 5793. Amplicons were cloned into pGEM-T. To construct the
mutant pDM138 constructs, the pERRE-1A primers described above were used
to PCR amplify the respective mutants from the pGEM-T background and clone
them into the ClaI restriction site of pDM138.
pSF2/ASF was generated from the PET9c-SF2 plasmid, obtained from Adrian
Krainer, Cold Spring Harbor Laboratory (21). The cDNA region corresponding
to SF2/ASF was cloned as two fragments, BglII-KpnI (⫺100 to ⫹242; numbering
based on ⫹1 at the initiation AUG) and KpnI-BamHI (⫹242 to a BamHI site
downstream of the UAA terminator). These were inserted into the eukaryotic
expression vector pCMV5 (provided by Mark Stinski, University of Iowa) which
had been cleaved with BglII and BamHI.
Synthesis of RNA substrates. The plasmids containing the splicing substrates
were digested with SpeI (Gibco-BRL, Rockville, Md.) to create linearized templates for transcription of RNA splicing substrates. In vitro run-off RNA transcripts labeled with [32P]UTP (Amersham Pharmacia Biotech) were generated as
previously described (2). DNA templates for RNA binding analysis were amplified by PCR from p33k using 5⬘ primers containing a T7 promoter site (a diagram
of the substrates is shown in Fig. 3A). The primers used for the substrates were:
5⬘ primer, TAATACGACTCACTATAGGGAGGAACAGCATGGCAGAAT
CG, and 3⬘ primer, TTTCCACCAGTCATTTCTTC (RREp1, nt 5443 to 5535);
5⬘ primer, TAATACGACTCACTATAGGGAGGTGAAAGAAGAATCTAA
AG, and 3⬘ primer, CCACCAAAGTATTCCTCC (RREp2, nt 5489 to 5589);
5⬘ primer, TAATACGACTCACTATAGGGAGGTGACTGGTGGAAAAT
AGG, and 3⬘ primer, CCCTATATAATGTTGCTG (RREp3, nt 5523 to 5622);
5⬘ primer, TAATACGACTCACTATAGGGAGGCGGAGGAAGCAAGAGA
CC, and 3⬘ primer, CCTGCTAAGCATAACAGA (RREp4, nt 5458 to 5565).
The T7 promoter is underlined in the 5⬘ primers. Amplified DNA was phenolchloroform extracted, ethanol precipitated, and resuspended in RNase-free distilled water. The RREp5 DNA fragment was synthesized as two complementary
oligonucleotides containing the T7 promoter attached to EIAV nt 5485 to 5540.
Complementary DNA fragments were combined at equal molar amounts, heated
at 95°C for 5 min, and then slowly cooled to anneal.
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Expression and purification of GST-Rev. Escherichia coli BL21 transformed
with the pGST-Rev expression vector was grown overnight at 1/10 of the final
culture volume in NZY broth containing ampicillin (0.1 mg/ml). The next day,
cells were brought up to the final volume, grown for an additional 3 h, and then
induced with 1 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) for 5 h. After
induction, cells were washed three times and resuspended in 50 mM Tris (pH
8.0)–50 mM NaCl (TN buffer). Cells were lysed by sonication, and the supernatant was clarified by centrifugation at 10,000 ⫻ g. GST-Rev was purified by
binding to glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech)
overnight and washed three times with TN buffer. The fusion protein was eluted
with 15 mM reduced glutathione in 50 mM Tris (pH 8.0), concentrated with a
30-kDa cut-off filter concentrator (Millipore, Bedford, Mass.), and dialyzed
against TN buffer. Protein expression was confirmed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and immunoblotting with convalescent antiEIAV or anti-GST antiserum (Amersham Pharmacia Biotech), which detected
expression of the GST-Rev fusion protein and several minor bands, including
GST alone (data not shown). In some cases, the fusion protein was digested with
4 U of Factor Xa protease (Amersham Pharmacia Biotech) per bead bed volume
while bound to glutathione-Sepharose beads. Excess GST and GST-Rev fusion
protein were removed with the glutathione-Sepharose beads, and the supernatant, containing cut Rev protein, was concentrated and dialyzed as described
above.
In vitro splicing and gel electrophoresis. Splicing reactions were carried out as
previously described (2). In brief, approximately 8 fmol of EIAV RNA substrates
was incubated for 2 h at 30°C with 60% (vol/vol) nuclear extract in Dignam’s
buffer D (12) containing 20 mM creatine phosphate, 3 mM MgCl2, 0.8 mM ATP,
and 2.6% (wt/vol) polyvinyl alcohol. In some experiments, EIAV Rev protein was
diluted in buffer D (12) and added to the splicing reaction mixtures at the
indicated concentrations. RNAs were analyzed on 4% polyacrylamide gels containing 7 M urea.
RNA binding assays and gel electrophoresis. RNA-protein interactions were
determined in 1⫻ RNA binding buffer, containing 10 mM HEPES-KOH (pH
7.5), 100 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 1 mM dithiothreitol, 50 g of
E. coli tRNA per l, and 10% glycerol. RNA was in vitro transcribed in the
presence of [32P]UTP as described above. From 100 ng to 2 mg of GST or
GST-Rev fusion protein was incubated with approximately 106 cpm of RNA
probe on ice for 15 min. The reactions were loaded directly onto an 8% native
100 mM Tris–glycine–polyacrylamide gel (37.5:1 acrylamide-bisacrylamide crosslinking ratio) which had been prerun for 1 h. The samples were electrophoresed
for an additional 3 h. The gel was fixed in 20% ethanol–10% acetic acid for 15
min, dried, and exposed to X-ray film with an intensifying screen.
CAT assays. Transient transfections and chloramphenicol acetyltransferase
(CAT) assays were performed with human embryonic kidney 293 cells and
canine fetal thymus (Cf2th) cells. Cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum and penicillin-streptomycin. CAT assays with 293 cells were performed as previously described (4).
Briefly, 1 g of either pcDNA3 (Invitrogen, Carlsbad, Calif.) or pRevWT was
transfected by calcium phosphate coprecipitation with 0.2 g of pDM138 reporter plasmid, 0.2 g of pCH110, and 0.6 g of pUC19. Two days posttransfection, cells were harvested, resuspended in 0.3 ml of 0.25 M Tris (pH 7.5), lysed
by freeze/thawing, and assayed for ␤-galactosidase activity to normalize CAT
assays for transfection efficiency. Normalized lysates were assayed for CAT
activity with 3 l of [14C]chloramphenicol and 1 mM acetyl coenzyme A. Acetylated products were separated by thin-layer chromatography, and the percent
acetylation was quantified with a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). Experiments were performed in triplicate, and the results summarize a minimum of six independent transfections.
Cf2th cells were used for in vivo competition assays. Cells were transfected
with 0.5 ng of pRevWT, 0.3 g of pERRE-1 reporter plasmid, and 10-fold
increasing concentrations (0 to 100 ng) of pSF2/ASF with 4 l of TransIT-LT
reagent (Mirus Corporation, Madison, Wis.). Each reaction mixture also included 0.2 g each of pCH110 and pUC19 to equalize the total amount of DNA
per reaction. Two days posttransfections, cells were harvested, and lysates were
assayed for ␤-galactosidase activity as above. Normalized lysates were assayed for
CAT activity with a commercially available CAT enzyme-linked immunosorbent
assay (ELISA) kit (Roche Molecular Biochemicals).

RESULTS
Purine-rich sequence required for exon 3 recognition. Exon
3 of the bicistronic, four-exon EIAV mRNA contains a purinerich sequence which resembles an ESE. Previous reports
showed that the SR protein SF2/ASF cross-links to the ESElike sequence in vitro and suggested that the ESE-like sequence may enhance exon 3 inclusion during pre-mRNA splicing (17). To further investigate the cis-acting requirements for
exon 3 inclusion, we constructed a series of DNA templates to
generate radiolabeled RNA substrates for in vitro splicing. All
substrates contained the exon 2 splice donor, the intervening
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FIG. 2. Exon 3 splicing requires the purine-rich sequence. (A) Diagram of
RNA substrates used for in vitro splicing, showing the locations of exons 2 and
3. All substrates contain the exon 2 splice donor and exon 3 splice acceptor. The
approximate location of the purine-rich sequence is highlighted. (B) After incubation for 2 h in HeLa cell splicing extracts, RNA products were electrophoresed
through 4% polyacrylamide gels and visualized by autoradiography. The locations of spliced and unspliced products are shown. The fastest-migrating products in lanes 3 to 5 are intron products resulting from splicing. Sizes are shown
at the left (in nucleotides).

intron, exon 3, and downstream sequences. Nested 3⬘ deletions
were made to identify splicing enhancer sequences present
within or downstream of exon 3 (Fig. 2A). Splicing of radiolabeled substrates was assayed in vitro with HeLa cell nuclear
extracts, which include all SR proteins. All constructs containing the purine-rich sequence were spliced (Fig. 2B, lanes 3 to
5), whereas no splicing was observed for the substrate lacking

VOL. 20, 2000

FIG. 3. Rev inhibits exon 3 splicing. GST-Rev or GST was added at the
indicated concentrations to the splicing reaction mixtures. The locations of the
splicing products are indicated on the right. Sizes are shown at the left (in
nucleotides).

the purine-rich sequence (Fig. 2B, lane 2). This is consistent
with the hypothesis that the purine sequence functions as an
ESE and is required for exon 3 inclusion in the multiply spliced
four-exon transcript. Taken together with previous work (17),
this suggests that exon 3 recognition requires SF2/ASF interactions at the ESE. The addition of as little as 100 ng of Rev
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to a splicing reaction mixture containing the largest splicing
substrate inhibited exon 3 recognition (Fig. 3). This confirms
earlier, in vivo observations of Rev-mediated changes of alternative splicing (17) and indicates that Rev is the only viral
protein necessary for exon 3 skipping.
Rev binds the ESE. Gontarek and Derse have suggested that
binding of EIAV Rev to a region of the viral pre-mRNA near
the ESE results in either direct or indirect inhibition of SR
protein function (17). In previous work, we identified an RRE
region spanning exon 3 (nt 5280 to 5834) (4). This favors a
mechanism by which Rev-RRE interactions disrupt SF2/ASF
binding at the ESE. To examine whether Rev binds at or near
the ESE, we generated a series of RNA probes and tested for
Rev-RNA interactions by RNA gel mobility shift assays with a
bacterially expressed and purified GST-Rev fusion protein.
The locations of the RNA probes relative to exon 3 and the
ESE are shown in Fig. 4A. GST-Rev bound to exon 3 probes
RREp1 and RREp2, both of which contain the ESE; however,
no binding was observed with the GST negative control (Fig.
4B, lanes 1 to 4). Minor binding was observed with RREp3
(Fig. 4B, lane 6), which has sequences immediately downstream of the ESE (nt 5523 to 5622), but lacks the purine-rich
region. The binding site was further delineated to a 57-nt
region of viral RNA by using two smaller ESE-containing
probes, RREp4 and RREp5. GST-Rev interacted with both
probes (Fig. 4B, lanes 8 and 11), further suggesting that Rev
binds at or near the ESE. To confirm the specificity of binding,
gel shift assays were performed with RREp2 in the presence
of excess unlabeled competitor RREp2 or RREp3 (Fig. 4C).
Excess unlabeled RREp2 inhibited GST-Rev binding (Fig.
4C, lanes 2 and 3), whereas no inhibition was observed with
RREp3 (Fig. 4C, lanes 4 and 5), demonstrating that the binding of GST-Rev to the ESE-containing RREp2 is specific. No
slower-migrating bands, indicative of Rev multimerization,
were observed in any of the RNA binding analyses, although
multimerization was readily observed with HIV-1 Rev when
used as a positive control (data not shown). The minor bands
in Fig. 4C represent GST-Rev and degraded by-products.

FIG. 4. GST-Rev binds the ESE in exon 3. (A) Locations of the RNA probes, relative to exon 3, used in RNA gel mobility shift assays. The purine-rich ESE
sequence is highlighted. SA, splice acceptor; SD, splice donor. (B) After incubation with GST or GST-Rev, radiolabeled RNAs were electrophoresed through 8% native
polyacrylamide gels. The locations of GST-Rev-RNA complexes are indicated with arrows. (C) Competition assays were performed with either 0.5 or 1 g of the
indicated excess of unlabeled competitor RNAs. Competitors were mixed with GST-Rev 10 min prior to the addition of radiolabeled probe.
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Overall, these results demonstrate that Rev specifically interacts with the viral RNA at or near the ESE.
Mutagenesis of the ESE reduces exon 3 splicing and Rev
binding. The finding that GST-Rev bound to a 57-nt region
containing the ESE suggested that a Rev-RNA interaction was
directly competing with SF2/ASF for binding at the ESE. If so,
there should be similar sequence requirements for exon 3
recognition and Rev binding. The ESE contains two purinerich sequences (designated A and B), which include seven
GAA repeats (Fig. 5A). GAA repeats have been shown to be
important for SF2/ASF recognition of ESE sequences in other
systems (reviewed in reference 16). Therefore, we constructed
five ESE mutations in the largest splicing construct and the
RREp4 RNA probe fragment which contained various GAA
to GCA mutations (Fig. 5A). The mutant templates were
tested for in vitro splicing and GST-Rev binding. Mutation of
all GAA motifs (mutAll) or the B-purine stretch (mutB) resulted in a decrease in both exon 3 in vitro splicing (Fig. 5B,
lanes 3 and 5) and GST-Rev binding (Fig. 5C, lanes 2 and 4).
Mutation of the GAA repeats in only the B purine stretch
resulted in a more modest reduction in both in vitro splicing
and GST-Rev binding (Fig. 5B, lanes 6 and 7, and 5C, lanes
5 and 6). Mutation of GAA repeats in the A region (mutA)
did not appear to significantly affect either exon 3 splicing or
GST-Rev binding in vitro (Fig. 5B, lane 4, and 5C, lane 3),
suggesting that the B purine stretch alone contains cis-acting
sequences necessary for exon 3 recognition and GST-Rev binding. The finding that each mutation had comparable effects in
both assays suggests similar requirements in the ESE for both
exon 3 recognition and Rev binding, further supporting a
model of Rev inhibition of splicing through direct competition
with SR proteins for binding at the ESE.
ESE can function as an RRE to mediate RNA nuclear export. In other complex retroviruses, Rev functions to regulate
the export of incompletely spliced RNAs via interaction with
the viral pre-mRNA at a specific sequence called the RRE. We
had previously used the HIV-1-derived pDM138 reporter system to preliminarily map the RRE of EIAV to a region which
overlapped exon 3 (ERRE-1) (4). However, this fragment possessed only 52% of the activity of a reporter containing a much
larger fragment of EIAV (ERRE-All), suggesting that sequences further downstream enhanced Rev-mediated export.
The RNA binding data given above suggested that the functional sequence within ERRE-1 was the ESE sequence. To test
this, we constructed a pDM138 reporter plasmid, minRRE,
which contains only 57 nt of EIAV (nt 5485 to 5540, RREp5),
spanning the ESE and the remainder of exon 3. Transienttransfection assays in 293 cells demonstrated that the minRRE
reporter produced levels of CAT activity comparable to those
by ERRE-1 (Fig. 6A), but only 35% of the activity with ERREAll. This indicates that minRRE contains the functional RRE
in ERRE-1 but additional elements outside ERRE-1 may be
required for full export activity.
To confirm that the ESE is the RRE within minRRE, we
introduced the GAA-to-GCA mutations used for in vitro splicing and RNA binding assays (Fig. 5A) into a reporter vector
containing the same sequences present in the largest splicing
substrate (Fig. 2A). This vector, ERRE-1A, is 41 nt shorter
than ERRE-1 but exhibited similar levels of activity (Fig. 6A).

FIG. 5. In vitro splicing and RNA binding of ESE mutants. (A) Sequence of
two purine stretches (designated A and B) in exon 3. GAA repeats were mutated

to GCA in the largest splicing construct (Fig. 2A) and RNA probe RREp4 (Fig.
4A). (B) In vitro splicing analysis of mutant ESE constructs. The locations of
splicing products are indicated. Sizes are shown at the left (in nucleotides). (C)
RNA gel mobility shift assays detecting GST-Rev binding to the mutant probes.
The arrow points to the location of shifted RNAs.
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Rev mediates alternative splicing by binding at or near the
ESE to disrupt SF2/ASF interactions.
SR proteins inhibit Rev-dependent nuclear export. The finding that similar cis-acting sequences mediate nuclear export,
RNA binding, and exon inclusion suggested that EIAV Rev
directly competes with SF2/ASF for binding at a similar site on
the viral pre-mRNA. If so, increasing concentrations of SF2/
ASF would inhibit Rev-dependent nuclear export activity. To
test this, initial studies were done to determine the linear range
of Rev-dependent nuclear export activity. Based on these results, Cf2th cells were transfected with 0.5 ng of pRevWT and
10-fold-increasing concentrations of pSF2/ASF. Results indicated a significant, dose-dependent decrease in CAT levels in
the presence of pSF2/ASF (Fig. 7). This suggests that SF2/ASF
and Rev are mutually competitive and is consistent with the
conclusion that both proteins bind to nearly identical sequences on the viral pre-mRNA. Western blot analyses confirmed that SF2/ASF protein levels increased concomitantly
with increased amounts of transfected plasmid DNA (data not
shown). The level of Rev produced by a transfected Rev cDNA
was below the limit of detection by Western blot. Thus, we
could not eliminate the possibility that the decrease in Revmediated nuclear export activity resulted from quantitative
changes in Rev levels rather than changes in Rev binding.
DISCUSSION
In addition to its role in nuclear export of incompletely
spliced viral mRNAs, EIAV Rev mediates alternative splicing
of the four-exon multiply spliced EIAV mRNA (22). Gontarek
and Derse (17) demonstrated that both GST-Rev and the SR
protein SF2/ASF cross-link in vitro with exon 3 and proposed
a model in which Rev disrupts SR protein interactions required for exon inclusion. Consistent with these previous data,
we show that the purine-rich sequence is required for GSTRev binding and for exon 3 recognition in splicing reactions in

FIG. 6. EIAV ESE can function as an RRE. (A) pDM138-derived reporter
vectors containing various regions of the EIAV genome were used in transient
transfections with and without Rev, and CAT assays were performed in 293 cells
as described in Materials and Methods. The results are presented as the percent
acetylation. Experiments were performed in triplicate, and the results represent
the mean of at least nine independent transfections. Error bars denote the
standard error of the mean. (B) The ESE mutations indicated in Fig. 5A were
also introduced into the ERRE-1A reporter vector and assayed for CAT activity
in the presence and absence of Rev as described for panel A.

In all cases, mutation of the GAA repeats in the ESE significantly reduced Rev-dependent nuclear export activity (P ⬍
0.01) (Fig. 6B). The greatest reduction in activity was seen in
constructs containing mutations of all seven GAA repeats (mutAll) or the three repeats in the A purine stretch (mutA). The
reduction in activity in mutA indicates that this region, while
not necessary for GST-Rev binding, is required for RNA nuclear export. Mutations in the B region (mutB, B12, and B34)
also significantly reduced activity. Therefore, we conclude that
the B purine stretch functions in GST-Rev binding, exon 3
inclusion, and Rev-dependent nuclear export. Together, these
results indicate that the ESE sequence acts as an RRE and that

FIG. 7. SF2/ASF inhibits Rev-dependent nuclear export. pERRE-1 reporter
plasmid was cotransfected with 0.5 ng of pRevWT and increasing amounts of
pSF2/ASF. CAT levels were quantified by ELISA and are reported as picograms
of CAT per normalized lysate. Results represent the mean of six independent
transfections, and the error bars denote the standard error of the mean. Asterisks
indicate values significantly different (P ⬍ 0.05) from control transfections which
contained no pSF2/ASF.
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vitro. In addition, a 57-nt sequence containing the ESE was
shown to act as a functional RRE in a heterologous nuclear
export assay system. Mutation of GAA nucleotide repeats in
the ESE reduced GST-Rev binding, exon 3 splicing in vitro,
and nuclear export of ESE-containing pre-mRNA. transComplementation assays demonstrated that SF2/ASF inhibited Rev-dependent nuclear export in a dose-dependent manner. Therefore, both SF2/ASF-mediated exon 3 splicing and
Rev-mediated RNA export have similar cis-acting RNA requirements, and EIAV Rev and SF2/ASF appear to be mutually competitive. From these data, we conclude that the purinerich sequence within exon 3 of EIAV is both an ESE and a
functional RRE. Extending the earlier model (17), we propose
that Rev-mediated nuclear export requires binding at or near
the ESE and that this results in skipping of exon 3 through
direct inhibition of SF2/ASF-ESE interactions required for
recognition of exon 3 by the host cell splicing machinery. The
use of an ESE as an RRE is unprecedented among complex
retroviruses.
It is interesting that mutation of the 5⬘ purine stretch (mutA)
decreased nuclear export but appeared to have little effect on
GST-Rev binding in vitro. Studies with HIV-1 Rev also indicate that sequences in the HIV-1 RRE are required for nuclear
export but not for RNA binding (25, 26). While these observations have not been fully explained, it is likely that RNA
secondary structure may play a role. Secondary structure is a
key determinant for HIV-1 binding, multimerization, and function (7, 8, 10, 11, 24, 25, 27). No biochemical data are available
to date to confirm the proposed structure (17) of the EIAV
ESE/RRE, and it is not possible to predict the structural effects
of the mutations used in our study. Our data would suggest
that mutation of the 5⬘ purine stretch does not affect the
primary binding site of Rev but may alter distant structures
required for Rev-mediated nuclear export. It has been demonstrated that HIV-1 Rev multimerization occurs only after
binding to a primary site on the RNA, and furthermore, other
regions of the RNA are important for secondary binding (8, 10,
32). However, we were unable to observe Rev multimerization
in our RNA binding assays, including those assays containing
the ESE. Therefore, it remains unclear why mutA exhibited
reduced activity with no apparent defect in RNA binding. It is
also possible that binding of host cell proteins to the RRE may
be required to facilitate Rev export activity. Further studies
will be necessary to delineate the role of this purine region in
Rev-mediated nuclear export.
Interactions of Rev-like proteins with SR proteins have been
demonstrated in other complex retroviruses. SR proteins have
been shown to bind the HIV-1 RRE in a Rev-dependent manner (28). The same study also demonstrated that excess exogenous SF2/ASF could produce a dose-dependent inhibition of
HIV-1 Rev function in vivo. We have previously reported an
inhibition of EIAV replication in activated macrophages associated with a delay in the appearance of incompletely spliced
RNAs (31). The data presented here suggest that this inhibition may be a result of competition of SF2/ASF with Rev for
binding at the ESE. This hypothesis is supported by our data
showing that excess SF2/ASF provided in trans can inhibit Rev
function in transient-transfection assays. Together, these results suggest that the inhibition in activated macrophages may
be due to an increase in the level of SR proteins. It is known
that expression of SR proteins varies in cells at different states
of activation and differentiation (16, 30, 33), including an increased expression of the SR protein SRp30c in activated T
cells (30). However, little is yet known about the phenotype of
SR proteins in monocyte cells. Also, our data cannot rule out
the possibility that in addition to competing for binding at the
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RRE, Rev may also inhibit function via protein-protein interactions.
Previous reports have demonstrated that mutations in the
NES do not affect the alternative splicing activity of EIAV Rev
(4, 18). To date, no laboratory has identified a Rev protein
which is competent in nuclear export but deficient in alternative splicing. Therefore, it is not clear whether alternative splicing of exon 3 is merely a consequence of Rev-mediated nuclear
export or if it plays a separate role in virus replication. The
RREs of most complex retroviruses are located near the
SU-TM cleavage site or in the 3⬘ end of env. The location of
EIAV RRE in the 5⬘ env is unique and may be explained by the
requirement of the ESE for exon 3 inclusion. The env mRNA
is spliced with the exon 2 splice acceptor (Fig. 1). A singly
spliced mRNA using the exon 3 splice acceptor has not been
observed in infected cells and would encode a truncated Env
protein lacking the signal peptide. A singly spliced mRNA
using the exon 4 splice acceptor is observed, which produces a
truncated transmembrane protein from the alternate start codon present in exon 1. Therefore, the use of an ESE as an RRE
may function to silence recognition of exon 3 to eliminate
another singly spliced transcript. Although a number of retroviruses utilize cis-acting sequences such as ESEs to take advantage of cellular mechanisms of alternative splicing, EIAV
appears to be the only retrovirus to encode a trans-acting
protein that directly modulates SR-mediated alternative splicing. EIAV was the first lentivirus described and is smaller and
genetically less complex than the other lentiviruses. It is possible that the EIAV Rev-ESE interaction represents a transitional step in the evolution of the Rev-Rex pathway utilized by
most complex retroviruses. Interestingly, previous work in our
laboratory and others suggested that EIAV may possess two
separate RREs (4, 22). In the current study, reporter constructs containing the 57-nt ESE region showed significantly
reduced activity compared with the ERRE-All reporter construct, containing a larger portion of the env gene (Fig. 6A).
However, a second RRE has not been identified, nor is it clear
that such an element can function independently of the ESE to
mediate export of viral pre-mRNAs. Additional studies will
help to fully understand the biological and evolutionary significance of the EIAV Rev-mediated export pathway.
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